Sapient
Sapient is a biomarker discovery organization providing bespoke services for metabolomics, lipidomics and proteomics data generation and analysis, enabling biopharma sponsors to go beyond the genome to accelerate precision drug development.
Latest Content
    
        Product News
    
                
        
    
    
            Sapient Partners With Alamar Biosciences To Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines and Inflammatory Mediators
    Partnership complements Sapient’s mass spectrometry-based proteomics services, extends multi-omics solutions, and will enable development of NULISAseq™ assays under regulated guidance.
        
    
        Product News
    
                
        
    
    
            Sapient Announces Expanded, Enhanced Metabolite Identification Capabilities
    Expansion of metabolite identification database accelerates insights, translation of findings for small molecule biomarker studies.
        
    
        Product News
    
                
        
    
    
            Sapient Extends Multi-Omics Services With High Throughput Discovery Proteomics
    New methods enable deep coverage of the blood and tissue proteome, expand capabilities for dynamic biomarker discovery to include metabolites, lipids, and proteins.
        
    
        Product News
    
                
        
    
    
            Sapient’s High Complexity CLIA Laboratory Receives Accreditation From the College of American Pathologists
    Sapient has been awarded accreditation from the College of American Pathologists (CAP).
        
    
        Industry Insight
    
                
        
    
    
            Probing the Biomarker Landscape of Human Disease
    To find out more about the importance of improving biomarker discovery and how next-generation mass spectrometry-based systems can help to fill the current gap in biomarker technologies, Technology Networks spoke with Dr. Mo Jain.
        
    
        Webinar
    
                            Speed, Scale, Specificity: How Next-Generation Mass Spectrometry is Transforming Small Molecule Biomarker Profiling
On-Demand
    Speaking at Proteomics & Metabolomics 2022, Mohit Jain from Bruker, presented their talk on small molecule biomarkers in drug development.
        
    
        Video
    
                            Live from the Lab at Sapient: How timsTOF is helping to transform the speed and scale of small molecule biomarker discovery
    Join Bruker's Erica Forsberg with Sapient Founder & CEO Mohit Jain, & Co-Founder and Head of Analytical R&D, Jeramie Watrous as they take you behind the scenes of Sapient’s lab. 
        
            Advertisement